ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Chinese Biotech Raises $97 Million

by Jean-François Tremblay
May 25, 2015 | APPEARED IN VOLUME 93, ISSUE 21

The oncology research firm BeiGene has raised $97 million from private equity investors to sustain existing drug research programs. The company has three cancer drug candidates undergoing Phase I clinical trials and several other programs at the preclinical stage. Based in Beijing and employing 170 people, BeiGene is headed by the U.S. entrepreneur John V. Oyler, who previously launched the drug discovery services firm BioDuro in China.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment